Company intelligence / Profile preview

Deciduous Therapeutics

San Francisco, California, United Statesdeciduoustx.com ↗

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

Deciduous Therapeutics develops novel medicines aimed at activating the body's own immune system to clear senescent cells, which accumulate due to failed immune surveillance and contribute to inflammation and tissue dysfunction in age-related diseases. Their approach has shown promise in ameliorating disease pathologies linked with aging by targeting these underlying cellular mechanisms[1][6].

Therapeutic areas: OtherMetabolic Disorders
Modalities: Small molecule drugsMonoclonal antibodies
Industry: Biotech

Beyond the preview

Go deeper on Deciduous Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deciduous Therapeutics.

Explore the full profile